Anteo Diagnostics completes acquisition

Company News

Anteo Diagnostics Limited (ASX:ADO) has completed the acquisition of DIAsource Immunoassays SA.

The purchase is in accordance with the vendor funding agreement for €7.7 million announced on 6 January 2016, payable over a four-year term.
 
Anteo CEO Dr Geoff Cumming said the transaction transforms Anteo and is a critical step in implementing the company’s corporate strategy.
 
Dr Cumming added DIAsource provides the cornerstone to grow the company’s diagnostics business.
 
Anteo Diagnostics recorded a net loss of $4.22 million at 30 June 2015.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.